HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis.
about
Conservation and variability of dengue virus proteins: implications for vaccine designThe relationship between predicted peptide-MHC class II affinity and T-cell activation in a HLA-DRbeta1*0401 transgenic mouse modelIdentification of antigenic epitopes on human allergens: studies with HLA transgenic miceRestricted autoantigen recognition associated with deletional and adaptive regulatory mechanisms.Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice.Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice.Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice.HLA class II transgenic mice as models of human diseases.T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral driftHLA class II transgenic mice: models of the human CD4+ T-cell immune response.MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: Defining a novel mechanism of superantigen-induced immunCD4+ T cells target epitopes residing within the RNA-binding domain of the U1-70-kDa small nuclear ribonucleoprotein autoantigen and have restricted TCR diversity in an HLA-DR4-transgenic murine model of mixed connective tissue disease.Superantigens subvert the neutrophil response to promote abscess formation and enhance Staphylococcus aureus survival in vivoDQB1*06:02-Associated Pathogenic Anti-Myelin Autoimmunity in Multiple Sclerosis-Like Disease: Potential Function of DQB1*06:02 as a Disease-Predisposing AlleleTransgenic models of autoimmune disease.Identification of conserved and HLA promiscuous DENV3 T-cell epitopes.Multivalent recombinant protein vaccine against coccidioidomycosisCD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosisAnthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunityBacterial superantigens promote acute nasopharyngeal infection by Streptococcus pyogenes in a human MHC Class II-dependent manner.Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 alleleDirect enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramersIdentification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cellsMice lacking all conventional MHC class II genes.Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.Superantigens Modulate Bacterial Density during Staphylococcus aureus Nasal ColonizationAge-dependent loss of tolerance to an immunodominant epitope of glutamic acid decarboxylase in diabetic-prone RIP-B7/DR4 mice.Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.Prevention of Tumor Formation by Latent Gammaherpesvirus Infection.An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitopeGenetic aspects of immune-mediated adverse drug effects.Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis.Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models.Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic miceIdentification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice.Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice.Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis.
P2860
Q24288762-7B42C2D7-3A79-4A44-A357-97EF44D5014CQ24795875-061D2C1F-C2FD-4B3F-833D-6585777448B6Q24813616-5D1DE4BA-50AC-4866-BB3C-3E86EF071C34Q30492902-BCC5AF87-9EA0-488D-AC61-D04B8611F667Q33521713-9AB773FF-D90C-48D6-B4F4-AE32904AD6D3Q33554688-5D1E91A3-5DCF-422E-A388-6D32CCC73FF3Q33627084-29C6BCB6-E2EA-4B17-A988-05F9699C03BEQ33713285-4E513C7E-5481-49D7-935D-13BFDF1BF7EEQ33723154-F56E0E6C-6ACF-4F46-82EE-0F74E3862AE0Q33786540-2271DBA9-03CE-4321-95BF-D87F6EC9100CQ33815475-C6332158-2271-4820-B6C1-D4B314334B14Q33817263-81D539C6-41FA-423B-A552-D86B32473964Q34055564-5C9C668B-34B3-4338-BD3A-5C0D4F7A7574Q34298337-29C89823-1D52-44C5-A898-CFAF9282F307Q34349507-B7A771A1-26A2-4421-9A1B-69D94FC8826CQ34554029-B856499C-1F03-4D8E-B99C-027DBBC05F20Q35018972-6ED4212B-F204-492D-9188-F5B62E340705Q35073853-F99DE59C-E3CF-4F8B-BB16-56AB96CA5369Q35138054-159AE1BC-E48F-4DE4-9CA3-E06948A47A1CQ35161514-7F8DB1FE-3063-4420-A023-AA663B548E63Q35176156-566AD5E2-414F-4267-B661-7D3B92DBCEB7Q35220270-69F4BB30-6948-4969-92B6-1C6C6B6ECB26Q35294749-CE3986AA-2871-4F55-AA3E-3DBA029EF598Q35411077-CF4DA572-76EB-40BC-A62D-5126149A8CB9Q35573814-BD32A115-B440-43C4-B83A-87365FA02575Q35620743-109B9D11-1EB1-4F0E-9E67-AD8FD3B88E41Q35638576-61CDA165-C29C-4E8B-B227-10A2AE3D4324Q35662947-4EA4B585-BDD0-4A9F-AF5D-44210F8F0213Q35748417-DC408F82-A901-4EE4-9F5B-A3C3326E7EE7Q35751036-FCE4A204-7806-497A-AB12-F7FEB0C862F4Q35880650-728DDB39-5651-4A69-8946-0536067F07FDQ36017879-3EA27951-79A5-4740-826A-172C97146A18Q36028231-E93A5483-D1EB-463A-86AD-D3E3115F78D9Q36218461-CA7CF25E-1E26-42F6-A23F-D9E3B56CF25BQ36288434-CCC2F7AA-A758-4ABA-B5C3-BCA6C41BC8EFQ36456716-02DE48CB-4BDF-4D1A-98A0-B9C4FD4ED2B3Q36456744-0373D60E-4EE8-4F54-A183-A34C8CFBF847Q36537972-04B61416-676D-4323-8279-ACC221645CCCQ36737669-5F4F63A5-CFD8-41C5-B0E8-8ED2FB5E559BQ36768842-84E7A365-3D61-4BFB-B197-0602C4E07B56
P2860
HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
HLA-DR4-IE chimeric class II t ...... al allergic encephalomyelitis.
@en
type
label
HLA-DR4-IE chimeric class II t ...... al allergic encephalomyelitis.
@en
prefLabel
HLA-DR4-IE chimeric class II t ...... al allergic encephalomyelitis.
@en
P2093
P2860
P356
P1476
HLA-DR4-IE chimeric class II t ...... al allergic encephalomyelitis.
@en
P2093
Campbell R
Falcioni F
P2860
P304
P356
10.1084/JEM.183.6.2635
P407
P577
1996-06-01T00:00:00Z